Skip to main content

Table 2 Differences in clinical characteristics across phenotypes

From: Clinical phenotyping in sarcoidosis using cluster analysis

Characteristic1,2

1, N = 103

2, N = 45

3, N = 111

4, N = 114

5, N = 88

6, N = 93

q-value3

FEV1pp

104.4 (6.5) E

105.7 (11.5) E

91.8 (4.8) D

80.3 (6.1) C

71.2 (5.8) B

53.2 (12.4) A

< 0.001

FVCpp

104.3 (6.6) E

107.9 (12.2) E

87.5 (5.3) C

89.5 (8.7) D

72.2 (5.3) B

66.3 (15.2) A

< 0.001

FEV1/FVC

79.1 (4.8) D

76.4 (5.5) C

82.5 (4.0) E

70.3 (5.4) B

77.5 (6.2) C,D

63.5 (13.6) A

< 0.001

Duration of disease (years)

2.0 (1.7) A

16.5 (9.9) E

4.2 (3.8) B

6.3 (4.8) C

2.0 (1.8) A

11.1 (9.5) D

< 0.001

Ever treatment

39 (54.2%) A

16 (42.1%) A

52 (57.8%) A

74 (75.5%) B

54 (78.3%) B,C

75 (90.4%) C

< 0.001

Scadding stage

 0

19 (20.2%) B,C

22 (48.9%) D

32 (31.7%) C,D

18 (16.4%) B

7 (9.0%) A,B

4 (4.9%) A

< 0.001

 1

19 (20.2%) A

5 (11.1%) A

18 (17.8%) A

11 (10.0%) A

10 (12.8%) A

4 (4.9%) A

 2

39 (41.5%) B

8 (17.8%) A

33 (32.7%) A,B

35 (31.8%) A,B

47 (60.3%) C

21 (25.6%) A,B

 3

17 (18.1%) A

8 (17.8%) A

13 (12.9%) A

26 (23.6%) A

11 (14.1%) A

11 (13.4%) A

 4

0 (0.0%) A

2 (4.4%) A

5 (5.0%) A

20 (18.2%) B

3 (3.8%) A

42 (51.2%) C

BMI

28.8 (5.2) A

28.8 (6.0) A

31.8 (7.4) B

29.7 (6.1) A

32.9 (7.4) B

30.7 (7.3) A,B

< 0.001

Age at diagnosis

47.4 (11.0) B

41.0 (11.6) A

47.8 (10.5) B

47.2 (11.2) B

49.6 (9.7) B

43.7 (10.7) A

< 0.001

Female

56 (54.4%) A,B

30 (66.7%) B

70 (63.1%) B

47 (41.2%) A

47 (53.4%) A,B

39 (41.9%) A

0.004

Lofgren’s

6 (5.8%) A

3 (6.7%) A

6 (5.4%) A

0 (0.0%) A

1 (1.1%) A

1 (1.1%) A

0.016

Ever smoker

31 (30.4%) A,B

19 (42.2%) A,B

30 (27.0%) A

31 (27.4%) A

30 (34.1%) A,B

44 (47.3%) B

0.024

Race

 White

90 (90.0%) A

33 (75.0%) A

95 (86.4%) A

91 (79.8%) A

61 (72.6%) A

73 (81.1%) A

0.025

 Black

7 (7.0%) A

11 (25.0%) B

13 (11.8%) A,B

23 (20.2%) B

19 (22.6%) B

17 (18.9%) A,B

 Asian

1 (1.0%)

0 (0.0%)

1 (0.9%)

0 (0.0%)

2 (2.4%)

0 (0.0%)

 American Indian

1 (1.0%)

0 (0.0%)

0 (0.0%)

0 (0.0%)

1 (1.2%)

0 (0.0%)

 Other

1 (1.0%)

0 (0.0%)

1 (0.9%)

0 (0.0%)

1 (1.2%)

0 (0.0%)

Extrapulmonary Involvement

43 (41.7%)

21 (46.7%)

53 (47.7%)

62 (54.4%)

42 (47.7%)

38 (40.9%)

0.461

Cardiac

5 (4.9%)

6 (13.3%)

14 (12.6%)

23 (20.2%)

11 (12.5%)

12 (12.9%)

0.077

No. of organs

1.6 (1.0)

1.6 (1.1)

1.7 (1.1)

1.8 (1.0)

1.7 (1.0)

1.6 (1.0)

0.646

  1. 1Data presented: n (%); mean (SD)
  2. 2Statistical tests performed: Fisher’s exact test; Welch’s one-way ANOVA. For pairwise comparisons, 2-sample t-tests and logistic regression were performed; groups sharing the same letter (A, B, C, D, E) do not have significantly different means or proportions (q > 0.05)
  3. 3False discovery rate correction for multiple testing
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us